Corcept Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth quarter revenue was $181.9 million, compared to $135.4 million in Q4 2023, contributing to a full-year 2024 revenue of $675.0 million, up from $482.4 million in 2023.
Net income for Q4 2024 was $30.7 million, or $0.26 diluted net income per common share, while full-year net income reached $141.2 million, or $1.23 diluted net income per common share. The company ended 2024 with a strong cash and investments position of $603.2 million.
Looking ahead, Corcept provided 2025 revenue guidance in the range of $900 million to $950 million, reflecting confidence in continued growth of its hypercortisolism business. The company also highlighted significant pipeline progress, including the NDA submission for relacorilant in hypercortisolism and anticipated data from the ROSELLA trial in ovarian cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.